Endogenous neuroprotection in multiple sclerosis

Acta Neurologica Belgica

Volumn 110, Issue 1, 2010, Pages 26-35

  Gonsette, R E ^a  

^a National Multiple Sclerosis Center   (Belgium)

Author keywords

Antioxidants; Cannabinoids; Complement system; Integrated cell response; Ischemic preconditioning; Kynurenine; Multiple sclerosis; Neuroprotection

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; ALPHA TOCOPHEROL; ANANDAMIDE; ANTIOXIDANT; ASCORBIC ACID; BETA INTERFERON; BG 0012; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CATALASE; COMPLEMENT; DRONABINOL; FATTY ACID AMIDASE INHIBITOR; GLATIRAMER; GLUTATHIONE TRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KYNURENIC ACID; KYNURENINE; LAQUINIMOD; METHYLPREDNISOLONE; NATALIZUMAB; NEUROPROTECTIVE AGENT; ROQUINIMEX; SUPEROXIDE DISMUTASE; TGN 1412; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; URIC ACID;

ANTIOXIDANT RESPONSIVE ELEMENT; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; DRUG MEGADOSE; HUMAN; HUMORAL IMMUNITY; INJURY; ISCHEMIC PRECONDITIONING; MICROENVIRONMENT; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; STRESS; STROKE; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 77953725146     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Aboul-Enein F., Lassmann H. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol. 2005;109:49-55.
2. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A. et al. Preferential loss of myelinassociated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol. 2003;62:25-33.
3. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69:1696-700. (Pubitemid 350287126)
4. Anderson RF, Harris TA. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. Free Radic Res. 2003;37:1131-6.
5. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord. 2007;22:1133-7.
6. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003;23:2511-6.
7. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;23:2326-36.
8. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32-46.
9. Becker B. F. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14:615-31.
10. Benito C, Romero JP, Tolon RM, Clemente D, Docagne F. et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007;27:2396-402.
11. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005;202:445-55.
12. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S. et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801.
13. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R. et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007;130:2543-53.
14. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28:180-7.
15. Chiarugi A, Cozzi A, Ballerini C, Massacesi L, Moroni F. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalo - myelitis. Neuroscience. 2001;102:687-95.
16. Christen S, Bifrare YD, Siegenthaler C, Leib SL, Tauber MG. Marked elevation in cortical urate and xanthine oxidoreductase activity in experi - mental bacterial meningitis. Brain Res. 2001;900:244-51.
17. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, doubleblind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-92.
18. Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler. 2000;6:378-81.
19. Correa F, Docagne F, Mestre L, Clemente D, Hernangomez M. et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol. 2009;77:86-100.
20. Correa F, Hernangomez M, Mestre L, Loria F, Spagnolo A. et al. Anandamide enhances IL-10 production in activated microglia by targeting CB (2) receptors: Roles of ERK1/2, JNK, and NFkappaB. Glia. 2010;58:135-47.
21. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR. et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol. 1996;144:480-4.
22. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 2005;58:797-800.
23. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T (H) 17 cells. Clin. Immunol. 2009;131:298-307.
24. Deretzi G, Pelidou SH, Zacharakis G, Kyritsis AP. Serum levels of uric acid in patients with multiple sclerosis: a biological marker in clinical course and treatment of MS. Mult Scler. 2003;9(suppl 1): S100, P412.
25. Dinkova-Kostova AT, Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res. 2008;52: S128-38.
26. Dirnagl U, Meisel A. Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning? Neuropharmacology. 2008;55:334-44.
27. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S. et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol. 2001;248:121-6.
28. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL. et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002;80:101-10.
29. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain. 2009;132:377-82.
30. Freeman RS, Barone MC. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr Drug Targets CNS Neurol Disord. 2005;4:85-92.
31. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-89.
32. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M. et al. Regulatory T cells fail to suppress CD4 (+) Tbet (+) T cells in relapsing multiple sclerosis patients. Immunology. 2009;127:418-28.
33. Gao X, Chen H, Choi Hk, Curhan G, Schwarzschild MA. et al. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008;167:831-8. (Pubitemid 351451751)
34. Gonsette RE, Sindic C, D'hooghe MB, DeDeyn P, Medaer R. et al. Boosting endogenous protection in multiple sclerosis:the ASIIMS trial (Association of Interferon beta and Inosine in Multiple Sclerosis). Mult Scler, 2010, epub ahead of print.
35. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther. 2009;121:147-59.
36. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003;13:554-73.
37. Griffiths MR, Neal JW, Fontaine M, Das T, Gasque P Complement factor H, a marker of self protects against experimental autoimmune encephalo - myelitis. J Immunol. 2009;182:4368-77.
38. Guerrero AL, Martin-Polo J, Laherran E, Gutierrez F, Iglesias F. et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immuno - modulatory treatment. Eur J Neurol. 2008;15:394-7.
39. Handouk Y, Angeleri VA, Danni M, DeRiso S, Provinciali L. Increase of serum uric acid levels in multiple sclerosis during treatment with natalizumab. Mult Scler. 2008;14(suppl 1): S281, P888.
40. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L. et al. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand. 2005;112:93-6.
41. Hinson SR, Mckeon A, Fryer JP, Apiwattanakul M, Lennon VA. et al. Prediction of neuromyelitis optica attack severity by quantitation of complementmediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009;66:1164-7.
42. Holley JE, Newcombe J, Winyard PG, Gutowski NJ. Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes. Mult Scler. 2007;13:955-61.
43. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett. 2009 [Epub ahead of print].
44. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST. et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA. 1997;94:2528-33.
45. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM. et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalo myelitis and multiple sclerosis. Proc Natl Acad Sci USA. 1998;95:675-80.
46. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A. et al. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sci. 2009 [Epub ahead of print].
47. Insarova NG, Korshunova TS, Mzhel'skaia TI, Borisova TV. Metabolic disorders in Huntington's chorea. Zh Nevropatol Psikhiatr Im S S Korsakova. 1978;78:489-95.
48. Janoff A. Alterations in lysosomes (intracellular enzymes) during shock; effects of preconditioning (tolerance) and protective drugs. Int Anesthesiol Clin. 1964;2:251-69.
49. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ. et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegen eration. Ann NY Acad Sci. 2008;1147:61-9.
50. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci. 2009 [Epub ahead of print].
51. Kanemitsu H, Tamura A, Kirino T, Karasawa S, Sano K. et al. Xanthine and uric acid levels in rat brain following focal ischemia. J Neurochem. 1988;51:1882-5.
52. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E. et al. Efficacy and safety of oral fumara te in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463-72.
53. Kastenbauer S, Koedel U, Becker BF, Pfister HW. Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations. Eur J Pharmacol. 2001;425:149-52.
54. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ. et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:344-8.
55. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H. et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res. 1990;528:21-4.
56. Knapp CM, Constantinescu CS, Tan JH, Mclean R, Cherryman GR. et al. Serum uric acid levels in optic neuritis. Mult Scler. 2004;10:278-80.
57. Koch M, DeKeyser J. Uric acid in multiple sclerosis. Neurol Res. 2006;28:316-9.
58. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70:343-54.
59. Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med. 2007;85:1351-9.
60. Larumbe Ilundain R, Ferrer-Valls JV, Vines-Rueda JJ, Guerrero D, Fraile P. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease. Rev Esp Salud Publica. 2001;75:43-53.
61. Leung PY, Packard AE, Stenzel-Poore MP. It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection. Future Neurol. 2009;4:201-208.
62. Li Q, Nacion K, Bu H, Lin F. The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis. Am J Pathol. 2009;175:661-7.
63. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I. et al. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol. 2006;147:83-91.
64. Lin W, Kunkler PE, Harding HP, Ron D, Kraig RP. et al. Enhanced integrated stress response promotes myelinating oligodendrocyte survival in response to interferon-g. Am J Pathol. 2008;173:1508-17.
65. Lin W, Popko B. Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci. 2009;12:379-85.
66. Lin W, Bailey SL, Ho H, Harding HP, Ron D. et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immunemediated damage. J Clin Invest. 2007;117:448-56.
67. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006;13:385-92.
68. Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I. et al. Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J. 2004;23:169-79.
69. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 1989;23:73-81.
70. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain. 2008;131:1722-35.
71. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain. 2007;130:2800-15.
72. Mehindate K, Sahlas DJ, Frankel D, Mawal Y, Liberman A. et al. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem. 2001;77:1386-95.
73. Mestre L, Correa F, Arevalo-Martin A, Molina-Holgado E, Valenti M. et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem. 2005;92:1327-39. (Pubitemid 40389203)
74. Mhaille AN, Mcquaid S, Windebank A, Cunnea P, McMahon J. et al. Increased expression of endoplasmic reticulum stress-related signalling pathway molecules in multiple sclerosis lesions. J Neuropathol Exp Neurol. 2008;67:200-11.
75. Mizoguchi A, Bhan AK. A case for regulatory B cells. J. Immunol. 2006;176:705-10.
76. Moor E, Kohen R, Reiter RJ, Shohami E. Closed head injury increases extracellular levels of antioxidants in rat hippocampus in vivo: an adaptive mechanism? Neurosci Lett. 2001;316:169-72.
77. Mostert JP, Ramsaransing GS, Heersema DJ, Heerings M, Wilczak N. et al. Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci. 2005;231:41-4.
78. Mowry EM, Woo JH, Ances BM. Technology insight: can neuroimaging provide insights into the role of ischemia in Baló's concentric sclerosis? Review Nat Clin Pract Neurol. 2007;3:341-8.
79. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl. 2006;70:285-304.
80. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291-5.
81. Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992;12:400-7.
82. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T. et al. The CB (2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem. 2008;283:13320-9.
83. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. 2009;60:85-92.
84. Pandit A, Vadnal J, Houston S, Freeman E, McDonough J. Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. J Neurol Sci. 2009;279:14-20.
85. Peng F, Zhang B, Zhong X, Li J, Xu G. et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler. 2008;14:188-96.
86. Platten M, Ho PP, Youssef S, Fontoura P, Garren H. et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005;310:850-5.
87. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W. et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord. 2004;18:265-70.
88. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL. et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003;126:2191-202.
89. Ramos TN, Wohler JE, Barnum SR. Deletion of both the C3a and C5a receptors fails to protect against experimental autoimmune encephalomyelitis. Neurosci Lett. 2009;467:234-6.
90. Ramsaransing GS, Heersema DJ, De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur J Neurol. 2005;12:514-8.
91. Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P. et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett. 2002;331:63-5.
92. Rejdak K, Petzold A, Kocki T, Kurzepa J, Grieb P. et al. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsingremitting multiple sclerosis. J Neural Transm. 2007;114:1011-5.
93. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K. et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006;108:527-31.
94. Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G. et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factorbeta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci. 2006;1091:110-22.
95. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P. et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003;24:915-9.
96. Rodriguez M, Warrington AE, Pease LR. Invited Article: Human natural autoantibodies in the treatment of neurologic disease. Neurology. 2009;72:1269-76.
97. Rózsa E, Robotka H, Vécsei L, Toldi J. The Janus-face kynurenic acid. J Neural Transm. 2008;115:1087-91.
98. Rus H, Cudrici C, Niculescu F, Shin ML. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuro immunol. 2006;180:9-16.
99. Salvati P, Ukmar G, Dho L, Rosa B, Cini M. et al. Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog. Neuropsychopharmacol. Biol Psychiatry. 1999;23:741-52.
100. Sawai S, Umemura H, Mori M, Satoh M, Hayakawa S. et al. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis. J Neuroimmunol. 2009 [Epub ahead of print].
101. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101-7.
102. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B. et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an openlabel, baseline-controlled pilot study. Eur J Neurol. 2006;13:604-10.
103. Schraven B, Kalinke U. CD28 superagonists: what makes the difference in humans? Immunity. 2008;28:591-5.
104. Schreibelt G, VanHorssen J, VanRossum S, Dijkstra CD, Drukarch B. et al. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev. 2007;56:322-30.
105. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA. 2005;102:3483-8.
106. Shohami E, Mechoulam R. Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proc Natl Acad Sci USA. 2006;103:6087-8.
107. Sokka AL, Putkonen N, Mudo G, Pryazhnikov E, Reijonen S. et al. Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. J Neurosci. 2007;27:901-8.
108. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML. et al. Serum uric acid and multiple sclerosis. Neurol Sci. 2002;23:183-8.
109. Spitsin S, Hooper DC, Mikheeva T, Koprowski H. Uric acid levels in patients with multiple sclerosis: analysis in mono-and dizygotic twins. Mult Scler. 2001;7:165-6.
110. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF. et al. Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain. 2005;128:979-87.
111. Stella N. Cannabinoid signaling in glial cells. Glia. 2004;48:267-77.
112. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P. et al. Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination. Ann Neurol. 1998;43:465-71.
113. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-28.
114. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM. et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res. 2003;119:170-83.
115. Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S. et al. Neuroprotective effects of the complement terminal pathway during demyelination: Implications for oligodendrocyte survival. J Neuroimmunol. 2009;213:3-11.
116. Toncev G, Drakulic M, Knezevic Z. Treatment with interferon beta 1b (Betaferon) and serum uric acid levels: two year follow-up. Mult Scler. 2007;13(suppl 2): S90, P305.
117. Toncev G, Milicic B, Toncev S, Samardzic G. Correlation between serum uric acid levels in multiple sclerosis patients and activity of disease. Eur J Neurol. 2000;7(suppl 3):126 (abstract).
118. Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002;9:221-6.
119. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009;8:280-91.
120. Tsakiri A, Tsiantoulas D, Frederiksen J. Serum uric acid levels are decreased in patients with relapsingremitting multiple sclerosis, in particular during relapses. Mult Scler. 2008;14(suppl 1): S289, P888.
121. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L. The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. J Neurol Sci. 2009;283:21-7.
122. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD. et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45:1729-37.
123. Weisskopf MG, O'reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561-7. (Pubitemid 47283643)
124. Witting A, Chen L, Cudaback E, Straiker A, Walter L. et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci USA. 2006;103:6362-7.
125. Yao SY, Soutto M, Sriram S. Preconditioning with cobalt chloride or desferrioxamine protects oligodendrocyte cell line (MO3.13) from tumor necrosis factor-alpha-mediated cell death. J Neurosci Res. 2008;86:2403-13.
126. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A. et al. COX-2, CB2 and P2X7-immuno - reactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
127. Yu Z, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53:613-25.
128. Zamani A, Rezaei A, Khaeir F, Hooper DC. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients. Clin Neurol Neurosurg. 2008;110:642-3.
129. Zozulya AL, Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum Immunol. 2008;69:797-804.